FOLOTYN Agreement And Drug Development Liability - Schedule of Drug Development Liability Adjustments (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($)
Accrued Drug Development Expenses [Roll Forward]
Balance at December 31, 2016	$ 861
Balance at March 31, 2017	861
FOLOTYN [Member]
Accrued Drug Development Expenses [Roll Forward]
Balance at December 31, 2016	13,130
Transfer from long-term to current in 2017	0
(Less): Expenses incurred in 2017	(359)
Balance at March 31, 2017	12,771
FOLOTYN [Member] | Drug Development Liability Current [Member]
Accrued Drug Development Expenses [Roll Forward]
Balance at December 31, 2016	861
Transfer from long-term to current in 2017	359
(Less): Expenses incurred in 2017	(359)
Balance at March 31, 2017	861
FOLOTYN [Member] | Drug Development Liability Long Term [Member]
Accrued Drug Development Expenses [Roll Forward]
Balance at December 31, 2016	12,269
Transfer from long-term to current in 2017	(359)
(Less): Expenses incurred in 2017	0
Balance at March 31, 2017	$ 11,910